GDTC
$1.04
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
Recent News
CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects
As February begins, major U.S. stock indexes have shown a robust start, with the Dow Jones Industrial Average and S&P 500 posting significant gains. In such an optimistic market climate, investors often look beyond the well-known giants to explore opportunities in lesser-known areas like penny stocks. Though traditionally associated with high risk, penny stocks can offer intriguing prospects when supported by solid financials. This article will highlight three such companies that may provide...
Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress
CytoMed Therapeutics (GDTC) issued a statement to address recent statements containing “inaccurate and misleading” claims regarding the Company’s research programs, clinical progress, and operations.The company said, ” CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company’s scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress. CytoMed’s resea
CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
CytoMed Therapeutics ( NASDAQ:GDTC ) Full Year 2024 Results Key Financial Results Net loss: S$2.52m (loss narrowed by...